Role of Esophageal Stents in Benign and Malignant Diseases

Division of Gastroenterology and Hepatology, Veterans Affairs Medical Center and University of Kansas School of Medicine, Kansas City, Missouri 64128-2295, USA.
The American Journal of Gastroenterology (Impact Factor: 9.21). 12/2009; 105(2):258-73; quiz 274. DOI: 10.1038/ajg.2009.684
Source: PubMed

ABSTRACT These recommendations provide an evidence-based approach to the role of esophageal stents in the management of benign and malignant diseases. These guidelines have been developed under the auspices of the American College of Gastroenterology and its Practice Parameters Committee and approved by the Board of Trustees. The following guidelines are based on a critical review of the available scientific literature on the topic identified in Medline and PubMed (January 1992-December 2008) using search terms that included stents, self-expandable metal stents, self-expandable plastic stents, esophageal cancer, esophageal adenocarcinoma, esophageal squamous cell carcinoma, esophageal stricture, perforations, anastomotic leaks, tracheoesophageal fistula, and achalasia. These guidelines are intended for use by health-care providers and apply to adult, but not pediatric, patients. As with other practice guidelines, these guidelines are not intended to replace clinical judgment but rather to provide general guidelines applicable to the majority of patients. Clinicians need to integrate recommendations with their own clinical judgment, and with individual patient circumstances, values, and preferences. They are intended to be flexible, in contrast to standards of care, which are inflexible policies designed to be followed in every case. Specific recommendations are based on relevant published information. The quality of evidence and strength of recommendations have been assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system, which is a system that has been adopted by multiple national and international societies. The GRADE system is based on a sequential assessment of quality of evidence, followed by assessment of the balance between benefits vs. downsides (harms, burden, and costs) and subsequent judgment regarding the strength of recommendation.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In benign esophageal strictures, the inflammation reaction and tissue hyperplasia after stent placement greatly limit the stent retention time and subsequent scar formation, which becomes one of the main reasons to influence the long-term recurrence rate. A newly developed biodegradable electrospun drug-fibers coated stent (DFCS) was expected to be fabricated to inhibit inflammation and scar formation. The electrospun paclitaxel/poly(ε-caprolactone) (PCL) fibers integrally covered on the bare stent using rotating collection method. The paclitaxel entrapment did not significantly affect the physical properties of electrospun PCL fibrous membranes. The mechanical results demonstrated that electrospun fibers containing paclitaxel covered on the stent maintained original mechanical characteristics of the stent, and no membrane tearing or ablation were observed after hundreds of repeated compressions. Paclitaxel release profiles were mainly controlled via diffusion of drug through the drug content, and stable release of paclitaxel continued up to 32 days at pH 4.0. Higher inhibition smooth muscle cells proliferation rates were observed on fibrous membranes with higher paclitaxel content. DFCS showed significant decrease in tissue inflammation and collagen fibre proliferation, and was easily removed from esophageal part which had nearly no damages to the tissues in dog model. Therefore, DFCS may be a great potential to markedly attenuate stent-induced inflammation and scar formation in the esophageal stenosis therapy.
    Acta biomaterialia 06/2013; 9(9). DOI:10.1016/j.actbio.2013.06.004 · 5.68 Impact Factor
  • Source
    Therapeutic Gastrointestinal Endoscopy, 09/2011; , ISBN: 978-953-307-743-7
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Leakage after oesophageal anastomosis or perforation remains a challenge for the surgeon. Traditional management has been operative repair or intensive conservative management. Both treatments are associated with prolonged hospitalisation and high morbidity and mortality rates. Self-expanding metallic stents have played an important role in the palliation of malignant oesophageal strictures and the treatment of tracheoesophageal fistulae. However, self-expanding metal stents in benign oesophageal disease are associated with complications such as bleeding, food bolus impaction, stent migration, and difficulty in retrieval. The Polyflex stent is the only commercially available self-expanding plastic stent which has been used in the management of malignant oesophageal strictures with good results. This review will consider the literature concerning the use of self-expanding plastic stents in the treatment of oesophageal anastomotic leakage and spontaneous perforations of the oesophagus.
    Diagnostic and Therapeutic Endoscopy 07/2011; 2011(1070-3608):418103. DOI:10.1155/2011/418103


Available from